文献速递泌尿男性生殖肿瘤

基于STHLM3-MRI研究的前列腺癌磁共振成像或标准活检筛查的成本效益

Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study.
PubMed 文献 · JAMA Oncol · 2022-11-10

基于STHLM3-MRI研究的经济评估,采用微观模拟模型比较无筛查、每四年PSA标准活检筛查和MRI联合靶向及标准活检筛查。MRI筛查较标准活检筛查减少约50%的终生活检和过度诊断,增量成本效果比为53736美元/质量调整生命年,在瑞典属中等成本,有较高概率更具成本效益。

要点

  • MRI联合靶向及标准活检筛查较标准活检筛查减少约50%终生活检和过度诊断。
  • MRI筛查较无筛查降低终生前列腺癌死亡6%至9%。
  • MRI筛查增量成本效果比为53736美元/质量调整生命年,在瑞典属中等成本。

核心结论

  • 在瑞典55至69岁男性中,PSA检测后行MRI联合靶向及标准活检的筛查策略较传统PSA加标准活检路径有较高概率更具成本效益。
  • 作者认为MRI筛查可考虑用于瑞典前列腺癌的早期发现。

研究设计与样本

  • 基于STHLM3-MRI研究(NCT03377881)的经济评估,采用微观模拟模型,从终生医疗保健角度评估瑞典成年男性的无筛查和筛查策略。
  • 模拟对象为瑞典55至69岁男性,输入参数来自STHLM3-MRI研究和近期综述,于2022年5月进行单因素和概率敏感性分析。

主要发现

  • 标准筛查组603人随机,其中165人(27.4%)未接受标准活检;实验筛查组929人随机,其中111人(11.9%)接受了MRI或任何活检。
  • 与无筛查相比,筛查策略与终生前列腺癌相关死亡降低6%至9%相关。
  • MRI联合靶向及标准活检筛查的增量成本效果比为53736美元/质量调整生命年,在瑞典被归类为中等成本。
  • 相对于标准活检筛查,MRI筛查将终生活检数量和过度诊断均减少约50%,且较传统PSA筛查有较高概率具有成本效益。

临床怎么用

  • 作者认为MRI筛查可考虑用于瑞典前列腺癌的早期发现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The combination of prostate-specific antigen (PSA) testing with magnetic resonance imaging (MRI) for prostate cancer detection has rarely been evaluated in a screening context. The STHLM3-MRI screening-by-invitation study (NCT03377881) has reported the benefits of using MRI with subsequent combined targeted and standard biopsies compared with using standard biopsies alone. OBJECTIVE: To investigate the cost-effectiveness of prostate cancer screening using MRI with combined targeted and standard biopsies compared with standard biopsies alone among men aged 55 to 69 years in Sweden, based on evidence from the STHLM3-MRI study. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation study was conducted from a lifetime health care perspective using a microsimulation model to evaluate no screening and screening strategies among adult men in Sweden. Men aged 55 to 69 years in Sweden were simulated for no screening and screening strategies. Input parameters were obtained from the STHLM3-MRI study and recent reviews. One-way and probabilistic sensitivity analyses were performed in May 2022. INTERVENTIONS: No screening, quadrennial PSA screening using standard biopsies alone, and MRI-based screening using combined targeted and standard biopsies. MAIN OUTCOMES AND MEASURES: The number of tests, incidence, deaths, costs, quality-adjusted life-years (QALY), and incremental cost-effectiveness ratios (ICERs) were estimated. RESULTS: A total 603 men were randomized to the standard arm, 165 of these participants (27.4%) did not undergo standard biopsy; 929 men were randomized to the experimental arm, 111 (11.9%) of whom did undergo MRI or any biopsy. Compared with no screening, the screening strategies were associated with reduced lifetime prostate cancer-related deaths by 6% to 9%. Screening with MRI and the combined biopsies resulted in an ICER of US $53 736, which is classified as a moderate cost per QALY gained in Sweden. Relative to screening with standard biopsies alone, MRI-based screening reduced the number of both lifetime biopsies and overdiagnosis by approximately 50% and had a high probability of being cost-effective than the traditional PSA screening. CONCLUSIONS AND RELEVANCE: For prostate cancer screening, this economic evaluation study found that PSA testing followed by MRI with subsequent combined targeted and standard biopsies had a high probability to be more cost-effective compared with the traditional screening pathway using PSA and standard biopsy. MRI-based screening may be considered for early detection of prostate cancer in Sweden.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hao S, Discacciati A, Eklund M, et al. Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study. JAMA Oncol. 2022. PMID: 36355382. doi:10.1001/jamaoncol.2022.5252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。